This news release, still available on the Moderna website, states that Slaoui was made a director of Moderna https://news.modernatx.com/news/news-details/2017/Moncef-M.-Slaoui-Ph.D.-Joins-Modernas-Board-of-Directors/default.aspx. This states "July 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that Moncef M. Slaoui, Ph.D., has joined its Board of Directors. Dr. Slaoui served in several senior research & development (R&D) roles with GlaxoSmithKline PLC (GSK) during his time with the company, most recently as its Chairman of Global Vaccines. While at GSK, Dr. Slaoui also served on its Board of Directors for 11 years and led its global pharmaceutical R&D activities from 2006 through to 2015. In conjunction with Dr. Slaoui’s appointment to Moderna’s board, Lee Babiss, Ph.D., will be stepping down from his role as a director."
However, there is no evidence that he was actually registered as a director, nor was Lee Babiss: refer to the directors listed here: https://opencorporates.com/officers/655373036. This press announcement contains misinformation, to which the BMJ article refers. The big question is why? Any thoughts?
Question Hedley, the MHRA regulates medicines in the UK. Does the UK have similar legislation regulating drug safety as we do in the US, 1938 Food, Drug and Cosmetic Act? The Prep Act was put into US law in 2005. Does the UK have something similar or is the UK also using Prep as a liability shield for all pandemic EUA related products. It can get a bit confusing for non experts as you can see.
He was also a director of Moderna
https://www.bmj.com/content/383/bmj.p2486
This news release, still available on the Moderna website, states that Slaoui was made a director of Moderna https://news.modernatx.com/news/news-details/2017/Moncef-M.-Slaoui-Ph.D.-Joins-Modernas-Board-of-Directors/default.aspx. This states "July 27, 2017 — Moderna Therapeutics, a clinical stage biotechnology company that is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that Moncef M. Slaoui, Ph.D., has joined its Board of Directors. Dr. Slaoui served in several senior research & development (R&D) roles with GlaxoSmithKline PLC (GSK) during his time with the company, most recently as its Chairman of Global Vaccines. While at GSK, Dr. Slaoui also served on its Board of Directors for 11 years and led its global pharmaceutical R&D activities from 2006 through to 2015. In conjunction with Dr. Slaoui’s appointment to Moderna’s board, Lee Babiss, Ph.D., will be stepping down from his role as a director."
However, there is no evidence that he was actually registered as a director, nor was Lee Babiss: refer to the directors listed here: https://opencorporates.com/officers/655373036. This press announcement contains misinformation, to which the BMJ article refers. The big question is why? Any thoughts?
Thanks Alison..
I’m thinking - will get back…👍😁
Very interesting thank you Hedley. From the photo, it seems that Moncef Slaoui cannot smile, only sneer. Could that be a tell.
Question Hedley, the MHRA regulates medicines in the UK. Does the UK have similar legislation regulating drug safety as we do in the US, 1938 Food, Drug and Cosmetic Act? The Prep Act was put into US law in 2005. Does the UK have something similar or is the UK also using Prep as a liability shield for all pandemic EUA related products. It can get a bit confusing for non experts as you can see.